Cytokinetics Inc
NASDAQ:CYTK
Intrinsic Value
Cytokinetics, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one CYTK stock under the Base Case scenario is 39.24 USD. Compared to the current market price of 65.34 USD, Cytokinetics Inc is Overvalued by 40%.
Valuation Backtest
Cytokinetics Inc
Run backtest to discover the historical profit from buying and selling CYTK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cytokinetics Inc
Current Assets | 628.1m |
Cash & Short-Term Investments | 1.1B |
Receivables | 1.3m |
Other Current Assets | -489.9m |
Non-Current Assets | 196.3m |
Long-Term Investments | 40.5m |
PP&E | 147.7m |
Other Non-Current Assets | 8m |
Current Liabilities | 102.7m |
Accounts Payable | 85.7m |
Accrued Liabilities | 60.5m |
Other Current Liabilities | -43.5m |
Non-Current Liabilities | 1.1B |
Long-Term Debt | 607.4m |
Other Non-Current Liabilities | 500.6m |
Earnings Waterfall
Cytokinetics Inc
Revenue
|
7.5m
USD
|
Operating Expenses
|
-503.7m
USD
|
Operating Income
|
-496.2m
USD
|
Other Expenses
|
-30m
USD
|
Net Income
|
-526.2m
USD
|
Free Cash Flow Analysis
Cytokinetics Inc
CYTK Profitability Score
Profitability Due Diligence
Cytokinetics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Cytokinetics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
CYTK Solvency Score
Solvency Due Diligence
Cytokinetics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Cytokinetics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYTK Price Targets Summary
Cytokinetics Inc
According to Wall Street analysts, the average 1-year price target for CYTK is 96.96 USD with a low forecast of 60.6 USD and a high forecast of 128.1 USD.
Ownership
CYTK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CYTK Price
Cytokinetics Inc
Average Annual Return | 57.3% |
Standard Deviation of Annual Returns | 64.79% |
Max Drawdown | -44% |
Market Capitalization | 6.6B USD |
Shares Outstanding | 103 005 000 |
Percentage of Shares Shorted | 20.7% |
CYTK News
Last Important Events
Cytokinetics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Cytokinetics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cytokinetics, Inc. operates as a biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 253 full-time employees. The company went IPO on 2004-04-29. The company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv (CK-2127107), a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten (CK-274), a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-3772271 (CK-271), a second novel cardiac myosin inhibitor.
Contact
IPO
Employees
Officers
The intrinsic value of one CYTK stock under the Base Case scenario is 39.24 USD.
Compared to the current market price of 65.34 USD, Cytokinetics Inc is Overvalued by 40%.